Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US
|
|
- Mervyn Harris
- 5 years ago
- Views:
Transcription
1 :45-09:30 Opening and welcome + Honorary award Keynote lecture 08:45-08:55 Welcome address 08:55-09:00 Presentation of the TAT 2019 Honorary Award 09:00-09:30 TAT 2018 Honorary Award Keynote address 09:30-11:00 Liquid biopsies as biomarkers for early drug development Moderation: L.M. Ellis1, C. Massard2; 1Houston, TX/US, 2Villejuif, CEDEX/FR 09:30-09:35 Introduction C. Massard, Villejuif, CEDEX/FR 09:35-09:50 Technical insights on liquid biopsies: Available techniques, sensitivity, GMP 09:50-10:05 Liquid Biopsies for screening patients in early phase trials: The example of NSCLC 10:05-10:20 Liquid Biopsies for minimal residual disease assessment and preemptive strategies for cancer therapy: The example of BRAFmut Melanoma 10:20-10:35 Single circulating tumour cell genomics as a biomarker for early drug development N. Stoecklein, Düsseldorf, DE 10:35-10:50 Tumour mutational burden during treatment: Implications for immuno-oncology N. Rizvi, New York, NY/US 10:50-11:00 Q&A and conclusion
2 11:30-13:00 Emerging therapeutic strategies 11:30-11:50 Introduction R. Plummer, Newcastle Upon Tyne, Tyne and Wear/GB 11:50-12:10 DNA polymerase Theta (POLθ) as an anticancer target G. Higgins, Oxford, GB 12:10-12:30 Targeting the WNT pathway for cancer therapy D.S. Tan, Singapore, SG 12:30-12:50 Clinical development of oxidative phosphorylation (OXPHOS) inhibitors T. Yap, Houston, Surrey/US 12:50-13:10 HIF-2a E. Jonasch, Houston, TX/US 13:10-13:30 Q&A 14:00-15:30 Proffered Paper session 16:00-17:30 Learning from haemato-oncology trials Moderation: V. Ribrag, Villejuif, FR 16:00-16:05 Introduction V. Ribrag, Villejuif, FR 16:05-16:25 Epigenetic dysregulation in hematological malignancies O. Bernard, Villejuif, FR 16:25-16:45 PRMT5 in hematological malignancies A. Dhar, Collegeville, US 16:45-17:05 CARt or BITE R.C. Bargou, Würzburg, DE 17:05-17:25 Application of CRISPR screen to guide therapy for lymphoma H.G. Wendel, New York, US 17:25-17:30 Q&A
3 :00-10:30 Immune checkpoint combinations: How to marry rationally Moderation: M. Atkins1, M.E. Gutierrez2; 1Washington Dc, US, 2Hackensack, US 09:00-09:05 Maximizing the potential of IO combinations: Successes and failures M. Atkins, Washington Dc, US 09:05-09:25 The rationale behind immunotherapy combinations 09:25-09:45 Since cell sequencing to study mechanisms of resistance to develop upfront combinations B. Izar, Boston, US 09:45-10:05 Preclinical models to assess timing of combination regimens 10:05-10:25 Immuno-oncology combination in patients with pre-existing molecular alteration (EGFR ALK BRAF and other) M. Gutierrez, Hackensack, US 10:25-10:30 Q&A 11:00-12:30 Proffered Paper session
4 13:30-15:00 Immune checkpoint inhibitors with targeted agents: Challenging marriages Moderation: G. Curigliano, Milan, IT 13:30-13:35 Introduction: Making challenging marriages work T. Yap, Houston, Surrey/US 13:35-13:55 PARP and PD-1/PDL1 inhibition G. Curigliano, Milan, IT 13:55-14:15 PI3K/AKT + PD-1/PD-L1 inhibition S. Ansell, Rochester, US 14:15-14:35 MEK + PD-1/PD-L1 inhibition C. Massard, Villejuif, CEDEX/FR 14:35-14:55 Epigenetics and Immunotherapy I. Melero, Pamplona, ES 14:55-15:00 Q&A 15:30-17:10 Methodological issues in IO Moderation: J. Tabernero1, A.A. Adjei2; 1Barcelona, ES, 2Rochester, MN/US 15:30-15:50 Biomarkers & endpoints 15:50-16:10 Imaging biomarkers E.G..E. de Vries, Groningen, NL 16:10-16:30 Scheduling, dose optimisation E. Calvo, Madrid, ES 16:30-16:50 Complex innovative designs Y. Shyr, New York, US 16:50-17:10 Report from MDICT L. Seymour, Kingston, Ontario/CA 17:10-17:15 Rational study design in the immunogenomics era A.A. Adjei, Rochester, MN/US
5 :00-10:30 Monotherapy vulnerability- Cell cycle checkpoint and DNA damage/repair inhibitors 09:00-09:05 Introduction 09:05-09:25 DNA repair deficiency in ovarian cancer: Use of short-term patient-derived organoids to predict DNA repair inhibitor response A. D'Andrea, Boston, US 09:25-09:45 Monotherapy vulnerability to ATR inhibition: Tumors harboring ALT, ATM deficiency and other alterations R. Plummer, Newcastle Upon Tyne, Tyne and Wear/GB 09:45-10:05 Replication stress and DNA repair inhibitors 10:05-10:25 Trial designs and targeting DNA repair J. Mateo, Barcelona, ES 10:25-10:30 Q&A
6 11:00-12:30 KRAS Moderation: U. Banerji1, S. Bates2; 1Sutton, Surrey/GB, 2New York, US 11:00-11:20 Introduction S. Bates, New York, US 11:20-11:40 Update on the KRAS program at NCI 11:40-12:00 KRAS inhibitor ARS :00-12:20 AZD4785 KRAS antisense oligonucleotide: preclinical and clinical development M. Krebs, Manchester, GB 12:20-12:40 Phase I trial of RO a MEK-RAF inhibitor in solid tumours and myeloma driven by RAS driven cancers U. Banerji, Sutton, Surrey/GB 12:40-13:00 Q&A 13:30-15:00 Targeting oncogenes generated by gene fusions 13:30-13:35 Introduction 13:35-13:55 NTRK R. Doebele, Aurora, CO/US 13:55-14:15 Targeting RET V. Subbiah, Houston, US 14:15-14:35 TPRSSZ / FGFR J. Bellmunt, Boston, MA/US 14:35-14:55 ROS1 and ALK 14:55-15:00 Q&A
7 15:00-15:15 Take home messages and close 15:00-15:15 Take home messages and close
Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception
02.05.2019 12:00-13:00 Type: Industry Satellite Symposium 12:00-13:00 Type: Industry Satellite Symposium 13:00-13:30 Type: Opening session Title: Welcome reception Exhibition area 13:30-13:45 Type: Opening
More information:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationHall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
More information8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina
FIRST ANNOUNCEMENT 8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina The 8 th Conference of IAOC "Current
More informationS. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH
27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ;
More informationRoom A. Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH. Room A. Title: Opening and welcome.
13.12.2018 11:15-12:45 Type: Educational session Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH 11:15-11:35 Back to the basics P. Romero, Epalinges, CH 11:35-11:55
More informationAuditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES
08-04-2017 12:45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs 1 2 1 2 Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15
More informationS. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH
27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome and introduction S. Rauh 1, J. Douillard 2 ;
More informationMadrid March Manuel Hidalgo. Alberto Bardelli. Lillian Siu. Josep Tabernero. Application deadline February 23 rd
Spanish National Cancer Research Centre CNIO Frontiers Meetings 2015 Madrid 22 25 March 2015 New Trends in Anticancer Drug Development Application deadline February 23 rd Organisers Manuel Hidalgo Alberto
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationChair: W. Eberhardt, DE; S. Peters, CH. 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A. 13:30-13:45 Opening and Welcome Room B
13-04-2016 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A 13:30-13:45 Opening and Welcome Room B Chair: W. Eberhardt, DE; S. Peters, CH 13:45-14:15 Heine H. Hansen Award Lecture Room B 14:30-16:00
More informationW. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES
10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationPROGRAM. Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Thursday, May 4 Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada Molecular Tumor Board - Case Presentation Lillian L. Siu, Patricio
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationHigh risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)
Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific
More informationRelevance of Innovative Trial Design Today. Basket of Baskets and other Innovative Clinical Trials
Relevance of Innovative Trial Design Today Basket of Baskets and other Innovative Clinical Trials Outline Precision Medicine Clinical Trials Evolving Field Classic industry-sponsored design: single drug,
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationEvolution of Early Phase Trials: Clinical Trial Design in the Modern Era
Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational
More informationRoom A. P. Romero, Epalinges, CH. K. Kerr, Aberdeen, GB. J. Haanen, Amsterdam, NL. I. Melero, Pamplona, ES. Room A. G. Coukos 1, J.
13.12.2018 11:15-12:45 Type: Educational session Title: Introduction to immunotherapy in cancer Chair(s): Pedro Romero, CH; Keith Kerr, GB 11:15-11:35 Back to the basics P. Romero, Epalinges, CH 11:35-11:55
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationPaediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
22 August 2018 EMA/242738/2018 Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients 5-6 September 2018 30 Churchill
More informationScientific Meeting Report. Prof. C. Sessa. ESMO Publishing Working Group 8 th International Symposium on Targeted Anticancer Therapies TAT 2010
Scientific Meeting Report Prof. C. Sessa. ESMO Publishing Working Group 8 th International Symposium on Targeted Anticancer Therapies TAT 2010 Bethesda, MD, US March 4 6, 2010 Scientific Meeting Report
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationModeration: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU
03-03-2017 13:30-13:45 Opening and welcome Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT 13:30-13:45 Welcome to the Conference 13:45-14:15 Keynote lecture Auditorium Moderation: 13:45-14:15
More informationNew molecular targets in lung cancer therapy
New molecular targets in lung cancer therapy Giuseppe Pelosi Pathology Division, Science & Technology Park, IRCCS Multimedica, Milan Milan - Italy Advanced lung cancer (IIIB IV) Subtyping Oncogene addiction
More informationConverting Novel Therapeutic Models into Early Phase Clinical Trials
Converting Novel Therapeutic Models into Early Phase Clinical Trials James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute, NIH IOM National Cancer Policy
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationNieuwe behandelingsmethodes in de oncologie
Nieuwe behandelingsmethodes in de oncologie Vibeke Kruse MD PhD Medical Oncologist Clinical Pharmacologist Department of Medical Oncology UZ Gent 20 Juni 2017 Outline 1) Introduction 2) Systemic therapy
More informationHow could molecular profiling impact histology independent labels in the future?
How could molecular profiling impact histology independent labels in the future? Marlene Thomas Senior international scientific director for personalised healthcare F. Hoffman-La Roche Ltd The information
More informationEORTC LUNG CANCER GROUP GROUP MEETING
Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00 Board meeting 11.00 11.30 Arrivals & Welcome coffee 11.30 11.50 Welcome & Introduction New Board,, Membership status, Calendar
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationMulti-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
Multi-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer Sponsor: University of Birmingham Chief Investigator: Gary Middleton Chief Biostatistician:
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationOctober 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference
The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationSelumetinib (AZD6244; ARRY ) Pediatric MATCH. George Kirk June 2016
Selumetinib (AZD6244; ARRY-142886) Pediatric MATCH George Kirk June 2016 MEK activation and selumetinib MOA MEK is a fundamental component of the MAPK pathway a central oncogenic signalling pathway frequently
More informationLights and sheds of early approval of new drugs in clinical routine. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Lights and sheds of early approval of new drugs in clinical routine Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy RCT 5-10% pts «real» patients are here Clin. Pharm. Ther. 2012
More informationNEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY?
NEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY? STEVEN M. DUBINETT, MD CHIEF OF THE DIVISION OF PULMONARY AND CRITICAL CARE MEDICINE DIRECTOR, UCLA LUNG CANCER PROGRAM
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationNGS in Lung Cancer Cytology
Institute of Pathology NGS in Lung Cancer Cytology Spasenija Savic University Hospital Basel, Switzerland Disclosures Speakers honoraria and advisory boards: Astra Zeneca, BMS, MSD, Novartis, Pfizer, Roche
More informationRXDX-101 & RXDX-102. Justin Gainor, MD February 20 th, 2014
RXDX-101 & RXDX-102 Justin Gainor, MD February 20 th, 2014 Background Chromosomal fusions are important oncogenic drivers in NSCLC - ALK Rearrangements (4-6%) - ROS1 Rearrangements (1-2%) - RET Rearrangements
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationColon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationBeyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics Q1 2017 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement
More informationFALL MEETING. Sitges, 7th and 8th October, Venue. ME Sitges Terramar Hotel Passeig Marítim, Sitges, Barcelona
FALL MEETING Sitges, 7th and 8th October, 2018 Venue ME Sitges Terramar Hotel Passeig Marítim, 80 08870 Sitges, Barcelona Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationRoche Pharma Day 2015
Roche Pharma Day 2015 Molecular Information Garret Hampton VP, Oncology Biomarker Development Pharmaceuticals Division Personalized healthcare A cornerstone of the Genentech / Roche strategy Diagnostics
More informationESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
More informationMay 9, Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC Dear Dr. Almas:
May 9, 2018 Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC 29202 Dear Dr. Almas: On behalf of LUNGevity Foundation, the nation s preeminent lung cancer nonprofit that funds
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationForeign antigens in human cancers
Foreign antigens in human cancers Lorenzo Fanchi PhD student, Ton Schumacher Lab ESMO Preceptorship on Immuno-Oncology May 26th, 2017 IMMUNE CHECKPOINT INHIBITION SHOWS CLINICAL BENEFIT IN DIFFERENT TUMOR
More informationOctober 6-7, 2017 Marseille, France
Program Chairs M. Ahluwalia (US) E. Le Rhun (FR) P. Métellus (FR) M. Weller (CH) Scientific Committee M. Ahluwalia (US) Z. Ram (IL) F. Dhermain (FR) R. Soffietti (IT) E. Le Rhun (FR) M. Weller (CH) P.
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationMolecularly Targeted Therapies: Mechanisms of Resistance
An AACR Special Conference on Molecularly Targeted Therapies: Mechanisms of Resistance May 9-12, 2012 Westin San Diego San Diego, CA Wednesday, May 9 7:00 p.m.-8:00 p.m. Opening Keynote Session BRAF and
More informationJoAnne Worthington, MSN, RN-BC, OCN
JoAnne Worthington, MSN, RN-BC, OCN I wish to thank the CTC-ONS chapter for the monetary award and my employer- TriHealth- GSH 14CD, for the cost of registration and hotel to attend the 2017 ONS Congress
More informationSquamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression
Squamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression David R. Spigel, M.D. Program Director, Lung Cancer Research Sarah Cannon Research Institute Nashville, TN Case of NR: Initial
More informationHealth Economics of Stratified Medicines An Industry Perspective
Health Economics of Stratified Medicines An Industry Perspective Gavin Lewis, Global Head of Oncology Market Access, AstraZeneca Health Economics of Stratified Medicine, London 5 th October 2016 Health
More informationInfrastructure for Clinical Data Exchange
Infrastructure for Clinical Data Exchange Amy Abernethy, MD, PhD FEBRUARY 29 2016 Instrument Data Highly Structured Administrative Data Highly Structured Clinical Research Data Intentionally Structured
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationGoals. Aims and design of Phase I trials. Challenges in the new era of oncology. Complex and multidisciplinary Phase I.
Goals Aims and design of Phase I trials Challenges in the new era of oncology Complex and multidisciplinary Phase I Perspectives Drug Development...2007 Preclinical Phase I Phase II Phase III Phase IV
More informationTumor Biology and Experimental Therapeutics Program
Tumor Biology and Experimental Therapeutics Program Translational Genomic Unit Main research projects: - Characterization of the mechanism of platinum resistance in Epithelial ovarian cancer. - Analysis
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationMind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs
Mind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs Ignacio Garcia-Ribas MD, PhD Senior Medical Director Early Clinical Research & Development, Oncology Therapeutic Area Takeda
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationNCIC CTG New Investigators Course: Workshop II. Dongsheng Tu and Penelope Bradbury August 21-23, 2013
NCIC CTG New Investigators Course: Workshop II Dongsheng Tu and Penelope Bradbury August 21-23, 2013 Objectives Review practical aspects of the design of the phase II trial Discuss statistical considerations
More informationDOWNLOAD OR READ : UPDATE ON BIOMARKERS IN ASTHMA AN ISSUE OF IMMUNOLOGY AND ALLERGY CLINICS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : UPDATE ON BIOMARKERS IN ASTHMA AN ISSUE OF IMMUNOLOGY AND ALLERGY CLINICS PDF EBOOK EPUB MOBI Page 1 Page 2 update on biomarkers in asthma an issue of immunology and allergy clinics
More information